Yonsei University Health System, Gangnam Severance Hospital
Welcome,         Profile    Billing    Logout  
 11 Trials 
31 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kim, Seong - Geun
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting
3
200
Europe, US, RoW
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma
05/26
08/26
MARS-17, NCT05838742: A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain

Active, not recruiting
2
314
Europe, Canada, Japan, US, RoW
GSK3858279, Placebo
GlaxoSmithKline
Pain, Osteoarthritis, Knee
08/24
12/24
NCT05440370: Clinical Trial to Evaluate the Efficacy and Safety of MegaCarti® in Knee Cartilage Defects

Active, not recruiting
N/A
90
RoW
MegaCarti®, Microfracture
L&C Bio
Osteoarthritis, Knee
06/22
01/27
NCT03983512: PULSTA Transcatheter Pulmonary Valve Pre-Approval Study

Active, not recruiting
N/A
58
Europe, RoW
PULSTA TPV System
Taewoong Medical Co., Ltd., Avania
Heart Diseases, Pulmonary Valve Regurgitation, Pulmonary Valve Stenosis, Tetralogy of Fallot
09/22
12/26
LNC-MECA-004, NCT06249828: Clinical Trial to Evaluate the Efficacy and Safety of MegaCarti^® in Knee Cartilage Defects

Recruiting
N/A
60
RoW
MegaCarti^®, Microfracture
L&C Bio, PROMeDis
Osteoarthritis, Knee
04/25
04/25
NCT06049914: Combined Exercise and Nutrition Intervention for Possible Sarcopenia Among Older Adults in Primary Care

Recruiting
N/A
94
RoW
Experimental group
Kyunghee University Medical Center
Sarcopenia
12/24
12/24
KIM
NCT05970679: Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A

Completed
3
252
RoW
Ezetimibe/Atorvastatin 10/5 mg, Atorvastatin 5mg, Ezetimibe 10mg, Ezetrol Tab. 10mg, Atorvastatin 10mg, Lipiwon Tab. 10mg, DW1125 placebo, DW1125A placebo, DW1125E placebo, DW1125A-1 placebo
Daewon Pharmaceutical Co., Ltd.
Hypercholesterolemia, Dyslipidemia
04/23
04/23
STAMP, NCT05529056: Study of Atropine Therapeutic Effect on Myopic Progression

Recruiting
3
472
RoW
Atropine Sulfate 01, LPTAT01, Atropine Sulfate 02, LPTAT02, Atropine Sulfate 03, LPTAT03, Placebo, LPTAT04
LitePharmTech Co., Ltd.
Myopia, Children
06/23
12/23
NCT05743764: HU007 in Patients with Dry Eye Syndrome

Completed
3
328
RoW
HU007, Restasis, Moisview Eye drop
Huons Co., Ltd.
Dry Eye Disease
02/24
02/24
NCT06205797: To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)

Recruiting
3
312
RoW
HU-045, Xeomin®
Huons Biopharma
Glabellar Lines
11/24
03/25
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26
MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Recruiting
3
1594
Europe, Canada, US, RoW
Teclistamab, JNJ-64007957, Lenalidomide
Stichting European Myeloma Network, Janssen Pharmaceutica
Multiple Myeloma
04/28
04/32
CARTITUDE-6, NCT05257083 / 2021-003284-10: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Recruiting
3
750
Europe, Canada, Japan, US, RoW
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cilta-cel, JNJ-68284528, Cyclophosphamide, Fludarabine
Stichting European Myeloma Network, Janssen Research & Development, LLC
Multiple Myeloma
06/33
08/40
NaliCap, NCT04371224: (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer

Recruiting
2
200
RoW
Irinotecan Liposomal Injection [Onivyde], nal-IRI, Capecitabine, xeloda, 5-fluorouracil, 5FU, Leucovorin, LV
Seoul National University Hospital
Pancreatic Cancer
12/24
12/25
OPSIS, NCT05665387: Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia

Completed
2
79
US
0.1% STN1013600 ophthalmic solution, 0.3% STN1013600 ophthalmic solution, Placebo
Santen Inc.
Presbyopia
07/23
07/23
JACKPOT8, NCT04105010: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL

Completed
2
171
US, RoW
AZD4205
Dizal Pharmaceuticals
Relapsed or Refractory Peripheral T Cell Lymphoma
10/23
02/24
NCT05621317: A Safety and Efficacy Study of PVX108 in Children and Adolescents with Peanut Allergy

Active, not recruiting
2
90
US, RoW
PVX-108, Placebo
Aravax Pty Ltd
Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Immune System Diseases
11/25
06/27
PLATINUM, NCT05338619: A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy

Recruiting
2
77
RoW
Lazertinib, LECLAZA
Sung Yong Lee, Yuhan Corporation
Non-small Cell Lung Cancer Stage III, EGFR Positive Non-small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer
03/26
03/26
WU-KONG1, NCT03974022: Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer with EGFR or HER2 Mutation

Active, not recruiting
1/2
315
Europe, Canada, Japan, US, RoW
Sunvozertinib, DZD9008
Dizal Pharmaceuticals
Non-Small Cell Lung Cancer
07/24
07/25
BET-PSMA-121, NCT05413850: Anti-tumour Activity of (177Lu) RhPSMA-10.1 Injection

Recruiting
1/2
150
Europe, US
177Lu-rhPSMA-10.1 injection, 177Lu-rhPSMA-10.1, 18F-rhPSMA-7.3 injection, 18F-rhPSMA-7.3
Blue Earth Therapeutics Ltd, PSI CRO
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, MCRPC, Urogenital Neoplasms, Prostatic Neoplasms, Prostatic Diseases
08/26
10/26
NCT05276570 / 2022-003466-20: Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease

Active, not recruiting
1
275
Europe, RoW
ARO-RAGE, Placebo
Arrowhead Pharmaceuticals, Arrowhead Pharmaceuticals, Inc.
Asthma
03/25
03/25
NCT01522183: Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

Recruiting
N/A
3000
Europe, Canada, US, RoW
Alexion Pharmaceuticals, Inc., Syneos Health
Atypical Hemolytic-Uremic Syndrome
01/31
01/31
NCT06010654: Pivotal RCT to Test Safety and Efficacy of Digital Therapeutics 'ANZEILAX' for Managing Generalized Anxiety Disorder

Completed
N/A
96
RoW
Software as a Medical device, ANZEILAX
HAII corp.ltd
Generalized Anxiety Disorder
07/24
07/24
JS-CT-2024-02, NCT06591221: The Effectiveness of Chuna Maintenance Therapy for Chronic Bothersome Neck Pain

Recruiting
N/A
250
RoW
Chuna Maintenance Therapy
Jaseng Medical Foundation
Neck Pain, Chronic Pain
12/25
12/25
JS-CT-2024-04, NCT06572579: A Pilot Registry for Ultrasound-guided Pharmacopuncture

Recruiting
N/A
50
RoW
Ultrasound-guided pharmacopuncture treatment
Jaseng Medical Foundation
Neck Pain, Back Pain
12/25
12/25
SAT001-KP-003, NCT06742268: Extension Study on Safety and Rebound Effect of SAT-001 for Myopia in Children

Recruiting
N/A
40
RoW
Single vision spectacles
S-Alpha Therapeutics, Inc.
Myopia
10/25
07/26
COLO-BT, NCT05826743: Safety and Effectiveness Evaluations of the as an Treatment to the Proctectomy.

Recruiting
N/A
256
US
COLO BT™, COLO BT, Stoma Creation
JSR Medical Co., Ltd.
Colorectal Surgery, Colorectal Cancer, Rectal/Anal
03/25
06/25
Kang, Shinae
REMBRANDT, NCT04700436: Efficacy and Safety of EzetimiBe/Rosuvastatin in Diabetic Dislipidemia With Hypertriglyceridaemia

Recruiting
4
240
RoW
Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg), Suvast tablet 10 mg (Rosuvastatin 10 mg)
Seoul National University Hospital, Gangnam Severance Hospital
Endocrine System Diseases, Nutritional and Metabolic Diseases, Diabetes Mellitus, Type 2, Dyslipidemias
05/21
11/21
Chung, Junyoung
LNC-MECA-004, NCT06249828: Clinical Trial to Evaluate the Efficacy and Safety of MegaCarti^® in Knee Cartilage Defects

Recruiting
N/A
60
RoW
MegaCarti^®, Microfracture
L&C Bio, PROMeDis
Osteoarthritis, Knee
04/25
04/25
DongSik, Chae
LNC-MECA-004, NCT06249828: Clinical Trial to Evaluate the Efficacy and Safety of MegaCarti^® in Knee Cartilage Defects

Recruiting
N/A
60
RoW
MegaCarti^®, Microfracture
L&C Bio, PROMeDis
Osteoarthritis, Knee
04/25
04/25
Kim, Jaejin
NCT06010654: Pivotal RCT to Test Safety and Efficacy of Digital Therapeutics 'ANZEILAX' for Managing Generalized Anxiety Disorder

Completed
N/A
96
RoW
Software as a Medical device, ANZEILAX
HAII corp.ltd
Generalized Anxiety Disorder
07/24
07/24

Download Options